Espicom Business Intelligence Ltd, Dec 2009, Pages: 318
InjectableGenericDrugs: Prospects & Opportunitiesto 2013 For more than half of the injectable generics approved in recent years, just one or two manufacturers have received ANDA approvals and 86
Avalon Global Research, Oct 2010, Pages: 20
the business opportunities post expiry of major drug patents. 1. Background and Definitions
2. Market Size and Segmentation
2.1 Global Market Size
2.2 Genericand Innovator Injectable Markets
2.3
Espicom Business Intelligence Ltd, March 2010, Pages: 128
. Among her reports are the first edition of this report, plus
InjectableGenericDrugs: ProspectsandOpportunitiesto 2014
Emerging Opportunities in Controlled-Release GenericDrugs
Diabetes Drug
Espicom Business Intelligence Ltd, Oct 2011, Pages: 108
and biosimilar opportunities: high risk, high reward?
With annual sales counted in billions of dollars, these blockbuster drugs are undoubtedly attractive to companies developing generics and
Espicom Business Intelligence Ltd, April 2011, Pages: 118
pharmaceutical and healthcare market analysis experience. Her recent studies include:
- InjectableGenericDrugs: ProspectsandOpportunities,
- Emerging Opportunities in Inhalation and Nasal Spray Generic
Espicom Business Intelligence Ltd, May 2009, Pages: 250
and healthcare market analysis experience. Her recent studies include InjectableGenericDrugs: ProspectsandOpportunities, Emerging Opportunities in Inhalation and Nasal Spray GenericDrugs, Diabetes
Biophoenix Limited, July 2008, Pages: 210
this report?
Buy this report to gain an insight into the performance of statins and other lipid-modulating drugsand commercial implications of post-marketing clinical trials such as:
1. asteroid and
